Patient Card

Please show this card to all emergency and other healthcare providers.

For complete information on the side effects of BLINCYTO, patients should read the Package Leaflet and healthcare professionals should read the Summary of Product Characteristics.

Patient and Healthcare Professional (HCP) Information

My name is _____

In Case of Emergency contact _____

I am being treated with BLINCYTO, a treatment for B-precursor acute lymphoblastic leukaemia, which can lower my immune system, and I started treatment on _____

Before providing any treatment, please call my prescribing physician at the number below. If any medical evaluations are undertaken, please provide copies of all medical records, including any treatments and/or test results, to the doctor(s) named below.

	Name	Hospital	City	Phone Number
Haematologist Oncologist				
Haematology Nurse				

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get to Malta Medicines Authority, Sir Temi Zammit Buildings, Malta Life Science Park, San Gwann SGN 300 Malta or at http:/www.medicinesauthority.gov.mt/adrportal

Adverse reactions should also be reported to Cherubino Ltd on 21343270 or pharmacovigilance@cherubino.com.mt

Patient Card

Information about BLINCYTO®▼(blinatumomab)

BLINCYTO may cause:

1. Neurological events, including immune effector cell-associated neurotoxicity syndrome (ICANS). Signs and symptoms of this side effect may include:

    - uncontrolled shaking (tremor)
    - confusion
    - disturbances of brain function (encephalopathy)
    - difficulty in communicating (aphasia) and/or writing (dysgraphia)
    - seizure (convulsion)

2. Cytokine release syndrome. Signs and symptoms of this side effect may include:

    - fever
    - swelling
    - chills
    - dizziness or lightheadedness

Please seek **urgent** attention from your doctor or nurse immediately or seek emergency help if you experience any of these symptoms.

Additional Important Guidance:

- Do not drive or operate moving vehicles/heavy machinery or engage in hazardous activities whilst receiving BLINCYTO.

- Please report any side effects you may experience. Report the suspected side effect experienced to the Malta Medicines Authority, Sir Temi Zammit Buildings, Malta Life Science Park, San Gwann SGN 300 Malta or at http:/www.medicinesauthority.gov.mt/adrportal. Adverse reactions should also be reported to Cherubino Ltd on 21343270 or pharmacovigilance@cherubino.com.mt

[This Patient Card fulfills the conditions of the marketing authorization and has been approved by the competent authority.]